187 related articles for article (PubMed ID: 37202570)
1. Early Circulating Tumor DNA Dynamics Predict Neoadjuvant Therapy Response and Recurrence in Colorectal Liver Metastases: A Prospective Study.
Wang XY; Zhang R; Han JH; Chen SQ; Zhao FL; Chen H; Lin J; Fan J; Zhu WW; Lu L; Chen JH
Ann Surg Oncol; 2023 Aug; 30(8):5252-5263. PubMed ID: 37202570
[TBL] [Abstract][Full Text] [Related]
2. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
3. Recurrence Prediction by Circulating Tumor DNA in the Patient with Colorectal Liver Metastases After Hepatectomy: A Prospective Biomarker Study.
Liu W; Jin KM; Zhang MH; Bao Q; Liu M; Xu D; Wang K; Xing BC
Ann Surg Oncol; 2023 Aug; 30(8):4916-4926. PubMed ID: 37219651
[TBL] [Abstract][Full Text] [Related]
4. Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases.
Liu M; Bao Q; Zhao T; Huang L; Zhang D; Wang Y; Yan X; Wang H; Jin K; Liu W; Wang K; Xing B
Hepatol Int; 2024 Jun; 18(3):1029-1039. PubMed ID: 38427145
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
6. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
[TBL] [Abstract][Full Text] [Related]
7. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
[TBL] [Abstract][Full Text] [Related]
9. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
[TBL] [Abstract][Full Text] [Related]
11. ASO Author Refections: Early ctDNA Dynamics Outperform Conventional Tumor Markers in Predicting Neoadjuvant Therapy Response and Recurrence in Colorectal Liver Metastases.
Wang XY; Chen JH
Ann Surg Oncol; 2023 Aug; 30(8):5264-5265. PubMed ID: 37219652
[No Abstract] [Full Text] [Related]
12. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases.
Bolhuis K; van 't Erve I; Mijnals C; Delis-Van Diemen PM; Huiskens J; Komurcu A; Lopez-Yurda M; van den Broek D; Swijnenburg RJ; Meijer GA; Punt CJA; Fijneman RJA
EBioMedicine; 2021 Aug; 70():103498. PubMed ID: 34333237
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
Yue D; Liu W; Chen C; Zhang T; Ma Y; Cui L; Gu Y; Bei T; Zhao X; Zhang B; Bai Y; Romero A; Xu-Welliver M; Wang C; Zhang Z; Zhang B
Transl Lung Cancer Res; 2022 Feb; 11(2):263-276. PubMed ID: 35280315
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.
Gao Z; Huang D; Chen H; Yang Y; An K; Ding C; Yuan Z; Zhai Z; Niu P; Gao Q; Cai J; Zeng Q; Wang Y; Hong Y; Rong W; Huang W; Lei F; Wang X; Chen S; Zhao X; Bai Y; Gu J
J Transl Med; 2023 Jan; 21(1):63. PubMed ID: 36717891
[TBL] [Abstract][Full Text] [Related]
15. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.
Cabalag CS; Yates M; Corrales MB; Yeh P; Wong SQ; Zhang BZ; Fujihara KM; Chong L; Hii MW; Dawson SJ; Phillips WA; Duong CP; Clemons NJ
Ann Surg; 2022 Aug; 276(2):e120-e126. PubMed ID: 35737908
[TBL] [Abstract][Full Text] [Related]
16. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
17. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study.
Zhou J; Wang C; Lin G; Xiao Y; Jia W; Xiao G; Liu Q; Wu B; Wu A; Qiu H; Zhang F; Hu K; Xue H; Shen Z; Wang Z; Han J; Niu B; Xu Y; Yu Z; Yang L
Clin Cancer Res; 2021 Jan; 27(1):301-310. PubMed ID: 33046514
[TBL] [Abstract][Full Text] [Related]
18. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.
Rothé F; Silva MJ; Venet D; Campbell C; Bradburry I; Rouas G; de Azambuja E; Maetens M; Fumagalli D; Rodrik-Outmezguine V; Di Cosimo S; Rosa D; Chia S; Wardley A; Ueno T; Janni W; Huober J; Baselga J; Piccart M; Loi S; Sotiriou C; Dawson SJ; Ignatiadis M
Clin Cancer Res; 2019 Jun; 25(12):3581-3588. PubMed ID: 30862692
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
Lin PH; Wang MY; Lo C; Tsai LW; Yen TC; Huang TY; Huang WC; Yang K; Chen CK; Fan SC; Kuo SH; Huang CS
Front Oncol; 2021; 11():736769. PubMed ID: 34868925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
